Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. ACC Action Center

Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Comments
  • Overview

    Dr. Florin Rader reviews the results of treatment with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study in patients with obstructive hypertrophic cardiomyopathy (HCM). 

Recommended
Details
Comments
  • Overview

    Dr. Florin Rader reviews the results of treatment with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study in patients with obstructive hypertrophic cardiomyopathy (HCM). 

Schedule15 Dec 2024